• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene initiate aggressive forms of leukaemia, which are often refractory to conventional therapies. Many MLL-fusion partners are members of the super elongation complex (SEC), a critical regulator of transcriptional elongation, suggesting that aberrant control of this process has an important role in leukaemia induction. Here we use a global proteomic strategy to demonstrate that MLL fusions, as part of SEC and the polymerase-associated factor complex (PAFc), are associated with the BET family of acetyl-lysine recognizing, chromatin 'adaptor' proteins. These data provided the basis for therapeutic intervention in MLL-fusion leukaemia, via the displacement of the BET family of proteins from chromatin. We show that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. I-BET151 treatment in two human leukaemia cell lines with different MLL fusions alters the expression of a common set of genes whose function may account for these phenotypic changes. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin. In vivo studies indicate that I-BET151 has significant therapeutic value, providing survival benefit in two distinct mouse models of murine MLL-AF9 and human MLL-AF4 leukaemia. Finally, the efficacy of I-BET151 against human leukaemia stem cells is demonstrated, providing further evidence of its potent therapeutic potential. These findings establish the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.

Pubmed ID: 21964340

Authors

  • Dawson MA
  • Prinjha RK
  • Dittmann A
  • Giotopoulos G
  • Bantscheff M
  • Chan WI
  • Robson SC
  • Chung CW
  • Hopf C
  • Savitski MM
  • Huthmacher C
  • Gudgin E
  • Lugo D
  • Beinke S
  • Chapman TD
  • Roberts EJ
  • Soden PE
  • Auger KR
  • Mirguet O
  • Doehner K
  • Delwel R
  • Burnett AK
  • Jeffrey P
  • Drewes G
  • Lee K
  • Huntly BJ
  • Kouzarides T

Journal

Nature

Publication Data

October 27, 2011

Associated Grants

  • Agency: Wellcome Trust, Id: 092096
  • Agency: Medical Research Council, Id: G0800784
  • Agency: Medical Research Council, Id: G116/187
  • Agency: Cancer Research UK, Id:
  • Agency: Medical Research Council, Id:
  • Agency: Wellcome Trust, Id:

Mesh Terms

  • Animals
  • Cell Line, Tumor
  • Chromatin
  • Chromatin Immunoprecipitation
  • Disease Models, Animal
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Heterocyclic Compounds with 4 or More Rings
  • Humans
  • Leukemia, Myeloid, Acute
  • Mice
  • Models, Molecular
  • Multiprotein Complexes
  • Myeloid-Lymphoid Leukemia Protein
  • Oncogene Proteins, Fusion
  • Protein Binding
  • Proteomics
  • Transcription Factors
  • Transcription, Genetic